TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TPX-0005 at ASCO 2018: Data Presented from the Ongoing TRIDENT-1 Study


“TPX-0005 has demonstrated clinically meaningful and durable benefit in patients with ROS1 fusion-positive lung cancers and NTRK fusion-positive tumors,” said Alexander Drilon, M.D., a key investigator in the TRIDENT-1 Study and Clinical Director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center. “I continue to be encouraged by the preliminary antitumor activity … Continue reading TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TPX-0005 at ASCO 2018: Data Presented from the Ongoing TRIDENT-1 Study

When It Rains, It Pours


Op volle toeren.


November is Lung Cancer Awareness Month!! (& an update!)


Cancer On My Mind


Ha ha – I couldn’t help myself. My dedicated readers will recall from my last post, “The Other Shoe,” that although Xalkori continues to be totally amazing at controlling the cancer in my body, it is not doing so hot in my brain. So, as I predicted, I have amped up my participation in the … Continue reading Cancer On My Mind

My Lung Cancer Community


In the past, you’ve heard me blabbing about how grateful I am for cancer researchers who, not only discovered the ROS1 tumor mutation that is causing my cancer, but who also found a drug, a pill, that manages to work around the mutation allowing the gene to function properly. Thus my tumors shrank and have … Continue reading My Lung Cancer Community